  |
 |
        |
 |
 |
 |
 |
     |
|||||||||||||||||||||||||||||||||||||||||||||
 |
Conference Details : Topics |
  |
Register Online |
 |
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||||||
© 2006 Primary Care Network
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Conference Details : Topics |
|
Register Online |
|
|||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Overview
Atherothrombotic disease, including acute coronary syndrome, stroke/TIA and PAD (peripheral arterial disease), continues to be a world-wide challenge in terms of morbidity, premature death, and disability with tremendous costs to patients, health care systems and society. The diffuse nature of atherothrombosis (cardiovascular, cerebrovascular, or peripheral arterial) and the heightened risk of recurrence represent major challenges to the clinician. This lecture will overview current studies and treatment guidelines for PAD, ACS and Stroke and explore the role of primary care in long-term treatment of these patients.
Objectives
Identify the major risk factors for CAD (coronary artery disease), stroke, and PAD (peripheral arterial disease)
Describe 3 clinical conditions in which dual antiplatelet therapy is recommended
Faculty
Martin W. Schwarze, DO, FACC
Clinical Professor of Medicine
St. Louis University School of Medicine
St. Louis, MO
Lawrence E. Mieczkowski, MD
Clinical Associate Professor of Medicine
Wright State University School of Medicine
Medical Director, Center for Cardiometabolic Treatment
Dayton, OH
Overview
This course considers the growing complaint of insomnia in the primary care practice and offers practical approaches to diagnosis and treatment. With the immense importance of sleep, and the need to proactively address insomnia patients in the practice, this course will provide key steps to insomnia management leading to improved patient outcomes and overall health.
Objectives
Describe a patient-centered approach to the diagnosis of insomnia and development of a treatment plan
Apply the elements of a risk/benefit analysis for choosing a pharmacologic option to various patients at risk
Faculty
Gary Richardson, MD
Paul Doghramji, MD
Overview
The current use of lipid lowering therapy in clinical practice has fallen short of the recommendations of national guidelines. Clearly, not an easy venture when treating patients with dyslipidemia, many with multiple risk factors and many with resulting coronary events that may be preventable if patients were treated aggressively to meet the NCEP-ATP lll goals. This presentation will address the clinical challenges of goal attainment (lack of compliance, aggressive treatment by clinicians, not leaving patients 15 points from goals), and provide clinicians with the pathways and knowledge to help attain their patients to goal.
Objectives
Describe at least two challenges in treating dyslipidemia to NCEP-ATP III goals, implement strategies that will help to assess CHD risk accurately, and get patients to targeted goals
Identify patients at increased risk for cardiovascular events and develop a treatment plan with at least 2 lipid lowering strategies, including the use of multiple therapies, which will help these patients achieve guideline-based targets taking into consideration current lifestyle and pharmacologic treatment options available thus reducing overall cardiovascular risk
Faculty
Muredach P. Reilly, MB
Assistant Professor of Medicine and Pharmacology
University of Pennsylvania School of Medicine
Philadelphia, PA
John Russell, MD
Clinical Associate Professor of Family and Community Medicine
Temple University School of Medicine
Philadelphia, PA
Overview
Migraine is a chronic, debilitating disorder that affects approximately 28 million Americans of whom ~18% are women and ~6% are men. When compared to migraines that occur during other times of the month, menstrual migraine (MM) may last longer and be more severe, disabling, frequent, and more difficult to treat. This program will address the new advances in the understanding of MM, the role of hormones, and how to select an appropriate treatment based on individual patient characteristics.
Objectives
Recognize migraine in the differential diagnosis of headaches that impact patients ability to fully function in their daily activities and identify menstrual migraine in female patients
Identify management strategies for women with menstrual migraine including use of headache calendars, behavioral modifications and approaches to acute and preventive treatment
Faculty
Brian Koffman, MDCM
Clinical Professor, Department of Family Medicine
Keck School of Medicine, USC Family Practice
St. Jude Heritage Medical Group
Diamond Bar, CA
Vincent Martin, MD
Professor of Clinical Medicine, University of Cincinnati
Cincinnati, OH
Overview
An estimated 1 million cases of herpes zoster (shingles) occur annually in the United States. The incidence and severity of herpes zoster increase with advancing age to produce substantial negative effects on quality of life, activities of daily living, neuropsychological functioning, and social status, resulting in significant morbidity in older adults. While antiviral therapy reduces the incidence and severity of herpes zoster, it does not reliably prevent postherpetic neuralgia (PHN), the most common and debilitating clinical sequela of herpes zoster. Herpes zoster vaccination has been demonstrated to reduce the incidence of the disease and its complications. Clinical trial data have demonstrated significant reductions in the incidence of herpes zoster and PHN, as well as overall reductions in the burden of disease.
Objectives
Review the epidemiology and public health burden of herpes zoster and its most common complication, postherpetic neuralgia (PHN)
Discuss the benefits and limitations of current pharmacotherapies for herpes zoster and Postherpetic neuralgia (PHN), and evaluate clinical trial data on the efficacy and safety of herpes zoster vaccination
Faculty
Katherine E. Galluzzi, DO, FACOFP
Professor and Chairperson
Department of Geriatrics
Philadelphia College of Osteopathic Medicine
Philadelphia, PA
Lawrence D. Gelb, MD
Professor of Medicine, Department of Internal Medicine
Division of Infectious Diseases
Washington University School of Medicine
St. Louis, MO
Overview
Human papillomavirus (HPV) is the most common newly acquired sexually transmitted infection in the United States. It is a necessary cause of cervical cancer and genital warts, and is associated with other anogenital and head and neck cancers, and recurrent respiratory papillomatosis. Prevention of HPV infection through prophylactic vaccination provides a safe and effective option to reduce the health burden associated with HPV-related diseases. Two vaccines have been developed: a quadrivalent HPV (6, 11, 16, 18) vaccine, approved by the US Food and Drug Administration (FDA), and a bivalent HPV (16, 18) vaccine, currently under FDA review. Both vaccines have demonstrated lasting efficacy against HPV-associated cervical disease and are generally well tolerated. This program will review the health consequences of HPV infection; provide an update on the safety and efficacy of HPV vaccines, including recent data on efficacy in mid-adult women, duration of protection, and cross-protection against nonvaccine HPV types; and evaluate the benefits of widespread HPV vaccination in preventing HPV-related diseases.
Objectives
Describe the epidemiology, natural history and consequences of HPV infection
Evaluate the anticipated benefits of widespread HPV vaccination in preventing cervical and anogenital cancers, genital warts, and other HPV-related diseases
Faculty
EJ Mayeaux, MD
Professor of Family Medicine
Professor of Obstetrics and Gynecology
Associate Family Practice Residency Program Director
Department of Family Medicine
Louisiana State University Health Sciences Center
School of Medicine
Shreveport, LA
Daron G. Ferris, MD
Professor
Department of Family Medicine
Department of Obstetrics and Gynecology
Director, Gynecologic Cancer Prevention Center
Medical College of Georgia
Augusta, GA
Overview
More than 20 million people are affected by diabetes and of this population nearly 65% will suffer early cardiovascular death. To effectively treat diabetes and reduce the risk of a cardiovascular event, glucose levels must be monitored and quickly controlled through changes in intervention, as outlined by the ADA/EASD treatment algorithm. Recent data provided by the National Health and Nutrition Examination Surveys (NHANES) revealed that there is some overall improvement in reaching the appropriate treatment standards, however, with the number of diabetes cases increasing by 1.5 million each year and the recent labeling changes affecting therapeutic options, it is more important than ever to be familiar with the pharmacologic treatment options for type 2 diabetes and the associated cardiovascular risk.
Objectives
Identify the current goals for A1C, blood pressure, and lipid levels set forth by the American Diabetes Association and apply them to the treatment strategies listed on the ADA/EASD algorithm in an effort to choose the best therapeutic option for each individual patient
Assess when patients with type 2 diabetes require cardiovascular risk reduction in addition to glycemic control and develop evidence-based approaches to treatment based on the ADA/EASD algorithm by reviewing adverse events
Faculty
Patrick J. Boyle, MD
Professor of Medicine
University of New Mexico
Albuquerque, NM
Mark Stolar, MD
Associate Professor of Clinical Medicine
Northwestern University
The Feinberg School of Medicine
Chicago, IL
Overview
This program will underscore the need for early, aggressive, combination BP treatment in order to reach JNC 7 goals, in light of the effect hypertension and diabetes has on the pathogenesis of hypertensive renal damage. It will explain the mechanisms of action of the various antihypertensive drug classes and how clinicians can use this understanding when selecting a drug regimen. Based on recent and ongoing trials, the safest and most efficacious drug combinations will be discussed.
Objectives
Develop appropriate combination therapy regimens individualized to each diabetic hypertensive patientŐs established risk and comorbid conditions
Demonstrate an understanding of the role of Renin-Aniotensin-Aldosterone System blockers in the treatment of hypertension, the prevention of new onset diabetes, and prevention of progression in diabetic nephropathy by selecting the most appropriate treatment regimen for diabetic hypertensive patients
Faculty
John R. Steinberg, MD
Volunteer Faculty
University of Maryland School of Medicine
Baltimore, MD
Raymond R. Townsend, MD
Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
Overview
Chronic Constipation is a multi-symptom gastrointestinal motility disorder that negatively impacts the lives of approximately 33 million Americans. Due to the overlap in symptoms reported by patients with irritable bowel syndrome-constipation and chronic constipation, clinicians often find it challenging to differentiate between the two. With a changing landscape of therapeutic options available, it is imperative that clinicians be able to establish and accurate diagnosis so the proper foundation is provided for determining initial therapy and developing a treatment plan.
Objectives
Differentiate chronic constipation from other functional bowel disorders
Identify the therapies that can be used to treat chronic constipation and other functional bowel disorders
Faculty
Louis Kuritzky, MD
Clinical Assistant Professor
Dept. of Community Health & Family Medicine
University of Florida
Gainesville, FL
Suzanne Rose, MD, MSEd
Professor of Medical Education and Medicine, Division of Gastroenterology
Associate Dean for Academic and Student Affairs
Associate Dean for Continuing Medical Education
Mount Sinai School of Medicine
New York, NY
Overview
Allergic rhinitis (AR) is the most common allergic condition in the US, affecting nearly 40 million people. Although AR is associated with significant comorbidities, current therapies have proven only modestly successful. Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional will provide primary care physicians with practical, evidence-based solutions to the challenges of managing AR, with particular emphasis on finding effective treatments and ensuring patient compliance. Two nationally recognized allergy/immunology experts will lead each 75-minute presentation with 60 minutes of didactic lectures and case history presentation, and a 15-minute question-and-answer session. Interactive discussion and a dynamic audience response system will also be integrated into the session.
Objectives
Describe key clinical characteristics of allergic rhinitis, its associated comorbidities, and its impact on patient health and quality of life
Identify barriers to treatment success of allergic rhinitis (treatment-related, physician-related, and patient-related barriers) and adequate control of symptoms, and devise strategies for overcoming those barriers
Faculty
Jay Portnoy, MD
Sandra Gawchik, DO
Overview
Rheumatoid arthritis (RA) is a complex immunologic and chronic inflammatory disease that affects more than 2 million people in the United States. Characterized by inflammation of the joints, periarticular bone resorption and cartilage destruction, RA is also an inherently aggressive, systemic disease that leaves patients vulnerable to comorbidities such as cardiovascular disease, osteoporosis, lymphoma, infection, and stroke. While primary care clinicians may not directly treat the disease long term, they are the first to come in contact with potential RA patients. Therefore it is important for all clinicians to be aware of the necessary steps in RA diagnostic and treatment modalities.
Objectives
Identify 3 early warning signs of rheumatoid arthritis (RA)
Describe current and evolving treatment options for RA, and be alert to monitoring and side effects related to these therapies
Faculty
Arthur Weaver, MD, MS, FACP, MACR
Eric M. Ruderman, MD
Associate Professor of Medicine
Division of Rheumatology
Northwestern University Feinberg School of Medicine
Chicago, IL
Overview
TBD
Objectives
Faculty